Trial Profile

Efficacy study of vedolizumab in patients with moderate to severe ulcerative colitis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vedolizumab (Primary)
Indications Ulcerative colitis
Focus Therapeutic Use
Acronyms VEDO-IBD

Most Recent Events

09 Mar 2021 Primary endpoint has been met.
09 Mar 2021 Results analyzing real-world experience in patients with active UC who commenced therapy with vedolizumab and were followed prospectively for up to 54 weeks. published in the Digestive Diseases and Sciences
17 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com